Lawrence A Kenyon insider trades

Open-market stock purchases and sales by Lawrence A Kenyon, Chief Financial Officer at Outlook Therapeutics, Inc, from SEC Form 4 filings since Jan 4, 2010.

Track record: 0% of 3 scored buys are up 5% or more since purchase, averaging -65%.

Recent trades

DateStockTradeValue
Aug 14, 2026OTLK Outlook Therapeutics, IncBought$111K
Jul 21, 2026OTLK Outlook Therapeutics, IncBought (not open market)—

Companies traded

  • OTLK Outlook Therapeutics, Inc: 3 buys, 2 sales, last Aug 14, 2026
  • ONS Oncobiologics, Inc: 2 sales, last Sep 18, 2018
  • ARNI Arno Therapeutics, Inc: other filings, last Feb 24, 2014
  • ACEL Tamir Biotechnology, Inc: other filings, last Jul 23, 2012
  • PRX PAR Pharmaceutical Companies, Inc: 13 sales, last Aug 2, 2010

Get free alerts when Lawrence A Kenyon files a new trade →